Search research articles
Contact Us
Filters
Showing results (91-100 of 106) with videos related to
Page
of 11
Sort By:
The Lancet. Oncology
|
October 14, 2019
Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial
Theodore W Laetsch, Gary Douglas Myers, André Baruchel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2022
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
Theodore W Laetsch, Shannon L Maude, Susana Rives, et al.
Transplantation and Cellular Therapy
|
June 10, 2022
The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials
Nosha Farhadfar, Kwang Woo Ahn, Stephanie Bo-Subait, et al.
Transplantation and Cellular Therapy
|
March 16, 2023
Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
Jeffery J Auletta, Jianqun Kou, Min Chen, et al.
Transplantation and Cellular Therapy
|
April 21, 2022
Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes
Rachel Phelan, Min Chen, Caitrin Bupp, et al.
Blood Advances
|
August 8, 2022
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium
Heather E Stefanski, Anne Eaton, Christina Baggott, et al.
Blood Advances
|
November 18, 2021
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report
Vanessa A Fabrizio, Christine L Phillips, Adam Lane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2025
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Monzr M Al Malki, Stephanie Bo-Subait, Brent Logan, et al.
Transplantation and Cellular Therapy
|
September 30, 2025
Corrigendum to: Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A Report from the CIBMTR, Transplantation and Cellular Therapy, 31:8, August 2025, 505-532; Article Number: JTCT-S-25-00377
Stephen R Spellman, Ke Xu, Temitope Oloyede, et al.
Blood Advances
|
May 17, 2022
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia
Amy Moskop, Lauren Pommert, Christina Baggott, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 106) with videos related to
Sort By:
Page
of 11
The Lancet. Oncology
|
October 14, 2019
Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial
Theodore W Laetsch, Gary Douglas Myers, André Baruchel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2022
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
Theodore W Laetsch, Shannon L Maude, Susana Rives, et al.
Transplantation and Cellular Therapy
|
June 10, 2022
The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials
Nosha Farhadfar, Kwang Woo Ahn, Stephanie Bo-Subait, et al.
Transplantation and Cellular Therapy
|
March 16, 2023
Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
Jeffery J Auletta, Jianqun Kou, Min Chen, et al.
Transplantation and Cellular Therapy
|
April 21, 2022
Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes
Rachel Phelan, Min Chen, Caitrin Bupp, et al.
Blood Advances
|
August 8, 2022
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium
Heather E Stefanski, Anne Eaton, Christina Baggott, et al.
Blood Advances
|
November 18, 2021
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report
Vanessa A Fabrizio, Christine L Phillips, Adam Lane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2025
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Monzr M Al Malki, Stephanie Bo-Subait, Brent Logan, et al.
Transplantation and Cellular Therapy
|
September 30, 2025
Corrigendum to: Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A Report from the CIBMTR, Transplantation and Cellular Therapy, 31:8, August 2025, 505-532; Article Number: JTCT-S-25-00377
Stephen R Spellman, Ke Xu, Temitope Oloyede, et al.
Blood Advances
|
May 17, 2022
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia
Amy Moskop, Lauren Pommert, Christina Baggott, et al.
Page
of 11